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CC BY-NC-ND license (http://creativeMalnutrition in patients with chronic obstructive pulmonary disease (COPD) is associated with
cachexia, sarcopenia, and weight loss, and may result in poorer pulmonary function,
decreased exercise capacity, and increased risk of exacerbations. Providing nutritional supple-
mentation is an important therapeutic intervention, particularly for severely ill COPD patients
with malnutrition. Higher calorie intake through nutritional supplementation significantly in-
creases body weight and muscle strength, and improves quality of life in malnourished COPD
patients. Difficulties may be experienced by these COPD patients, who are struggling to
breathe and eliminate CO2 from the lungs, resulting in dyspnea, hypercapnia, hypoxia, and res-
piratory acidosis, which exacerbates muscle loss through oxidative stress and inflammatory re-
sponses. To overcome these problems, nutritional supplements should aim to reduce metabolic
CO2 production, lower respiratory quotient, and improve lung function. Several studies have
shown that high-fat supplements produce less CO2 and have lower respiratory quotient value
than high-carbohydrate supplements. In addition, high-fat supplements may be the most effi-
cient means of providing a low-volume, calorie-dense supplement to COPD patients, and may
be most beneficial to patients with prolonged mechanical ventilation where hypercapnia and
malnutrition are most pronounced. Further studies are required to investigate the optimal
nutritional supplements for COPD patients according to their disease severity.
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596 M.-J. Hsieh et al.IntroductionChronic obstructive pulmonary disease (COPD) is a life-
threatening lung disease caused mainly by long-term
exposure to cigarette smoke and other harmful airborne
pollutants. Permanent damage to the lung parenchyma
with loss of elastic recoil causes emphysema and inflam-
matory cell infiltration of the walls of the small airways,
resulting in chronic bronchiolitis and bronchitis. The
severity of COPD was classified according to measurements
of airflow obstruction by determining the degree of FEV1
(forced expiratory volume in the 1st second) reduction.
However, FEV1 alone does not reliably identify severity of
breathlessness, exercise limitation, or impairment of
health. The Global Initiative for Obstructive Lung Disease
has published the classification system for COPD disease
severity with revising the staging system based on FEV1
alone.1 This classification may allow diagnoses of 60e85% of
undiagnosed patients who have mild to moderate dis-
ease.1,2 The new Global Initiative for Obstructive Lung
Disease guidelines categorize COPD patients into four
groups by combining the spirometric measurements with
symptomatic assessments, using established questionnaires
(COPD Assessment Test, Clinical COPD Questionnaire, or
modified Medical Research Council Dyspnea Scale), and the
evaluation of the risk of future exacerbations, based on the
patient’s history of exacerbations in the previous year.1
There is no cure for COPD patients, and the major goals
of treatments involve management of the patients’ symp-
toms. As well as reduced lung function, patients with COPD
tend to have poor health related quality of life, with
approximately a third of these patients suffering from
malnutrition. Their breathing difficulties not only affect
their exercise capacity but also cause a loss of appetite and
decreased nutritional intake, resulting in a spiraling
malnourished state. Malnutrition is more common in pa-
tients with emphysema than chronic bronchitis, and may be
either a cause of further degeneration of the disease or a
consequence of disease progression.3,4
There is mounting evidence that in COPD patients with
low body mass index and/or fat-free mass index (FFMI) are
associated with a poorer prognosis and impaired long-term
survival.3 Malnutrition further aggravates the problems in
COPD patients as respiratory muscle strength is reduced
leading to cachexia, with a significant loss of appetite and
exercise intolerance.5e7 Furthermore, COPD patients tend
to be elderly, and the loss in skeletal muscle mass as part of
the natural aging process, may be further exacerbated by
COPD as a result of malnutrition, sarcopenia, and
cachexia.6
Sarcopenia is defined as the loss of skeletal muscle mass
through the inability to generate new muscle cells, and also
through the atrophy of existing muscle fibers.6,8 The rela-
tionship among sarcopenia, physical performance, and
respiratory function test was investigated in 71 patients
with COPD aged > 65 years.9 In these well-nourished COPD
patients, linear regression analysis revealed that respira-
tory function was a better predictor of physical perfor-
mance compared with body muscle mass parameters.
However, in sarcopenic COPD patients with moderate dis-
ease severity, the proportion of fat-free mass (FFM) was
significantly reduced compared with healthy matchedcontrols, although the fat mass was similar between the
two groups, suggesting a similar lipolytic rate.10
It is widely accepted that COPD patients who are
malnourished with low body weight are at greatest risk of
further exacerbations,11 with increased risk of hospital
readmittance,12 and have higher mortality rates.13 Interest-
ingly, in COPDpatientswhowere considered to be overweight
or obese, there was evidence of a reduced risk of hospitali-
zation, and reduced mortality rates.11e13 The reason that
these overweight/obese patients have a better prognosis is
probably attributable to the physiological advantages.
There is mounting evidence from large, multicenter
studies demonstrating that in patients with moderate to
severe COPD, low FFMI was a statistically significant pre-
dictor of mortality, independent of other factors.14e17 In
the elderly COPD population, sarcopenia is accelerated by
as much as 30% in patients with mild to moderate COPD.16
This is in addition to skeletal muscle loss due to the natu-
ral process of aging. The results from these studies support
the assessment of body composition as a very important
diagnostic marker of disease severity in COPD.
Inflammation in COPD
There is evidence to suggest that, in addition to inflam-
matory responses to the respiratory tissues, inflammation
may be an important factor affecting the loss of skeletal
muscle mass in COPD patients. The detection of high levels
of circulating proinflammatory cytokines such as tumor
necrosis factor (TNF), interleukin (IL)-6, and IL-1b in COPD
patients with cachexia, have led to claims that COPD is a
“chronic systemic inflammatory syndrome.”18 Systemic
inflammation and oxidative stress do play a role as patho-
logical mechanisms involved in muscle dysfunction in COPD.
Chronic inflammation may have a detrimental effect on
muscle catabolism. The action of inflammatory cytokine
TNF binding to its receptor on muscle cells results in
apoptotic muscle cell death. Furthermore, muscle anabo-
lism may be affected during chronic inflammation as the
available amino acid pool may become depleted, through
synthesis of acute phase proteins, thus preventing replen-
ishment of muscle protein stores.19 Indeed, glutamate, the
amino acid salt form of glutamic acid, has been shown to be
low in concentration in the plasma of COPD patients.19
Cachectic COPD patients with moderate disease have
lower plasma concentrations of glutamate and branched-
chain amino acids (BCAAs) than those in the control and
noncachectic COPD groups, and demonstrate a higher
whole-body myofibrillar protein breakdown.19
Oxidative stress in COPD
In addition to chronic inflammation, oxidative stress may
further aggravate muscle degeneration and other symptoms
in COPD patients. There may be an imbalance between O2
and CO2 levels in the blood, creating hypoxic conditions in
the cells and muscles, leading to the production of reactive
oxygen species. It has been proposed that the loss of
muscle mass in COPD patients may not solely result from
physical inactivity, but that hypoxia, oxidative stress, and
muscle dysfunction also play a significant role.20 The
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expression of inflammatory mediators resulting in muscle
cell death through apoptosis and the degradation of actin
and myosin.21 Evidence for this has been shown with an
increase in lipid peroxidation, a marker for oxidative stress,
and reduction in antioxidants (reduced glutathione, cata-
lase, and glutathione peroxidase) in COPD patients
compared with healthy control individuals.22
Nutritional supplementation benefits body
weight control in COPD patients
Overall, 10e45% of patients with COPD are malnourished,
and it is evident that malnutrition and undernutrition are
important prognostic factors for COPD patients.23 A growing
number of studies looking at nutritional supplementation in
COPD patients have been performed and wished to improve
current clinical practice.3,24,25 A meta-analysis of 17 studies
assessing the impact of nutritional support on weight gain,
respiratory function, muscle strength, exercise capacity,
and quality of life revealed that nutritional supplementa-
tion promoted weight gain, with an increase in FFM, fat
mass, improved 6-minute walk distance, and skinfold
thickness in malnourished COPD patients.3 There were also
significant improvements in respiratory muscle strength and
overall quality of life in malnourished COPD patients. A
systematic review and meta-analyses of nutritional support
also found that in 12 randomized controlled trials, nutri-
tional supplements significantly improved respiratory mus-
cle strength, handgrip strength, weight gain (2 kg),
exercise performance, and quality of life.24 In another
meta-analysis of 13 randomized controlled trials of nutri-
tional supplements, nutritional advice, or enteral tube
feeding, a significant increase in mean total protein andTable 1 Summary of effects of nutritional supplementation on
Nutritional
supplement
COPD status Clinical outcom
High fat Stable ambulatory COPD Lower PaCO2, R
COPD with hypercapnia Lower PaCO2, R
Improved lung
Moderate to severe COPD Lower PaCO2, R
Higher PaO2
Improved lung
Severe COPD with artificial
ventilation
Lower PaCO2
Reduced time
High calories Depleted COPD Patients
Mechanically ventilated
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Increased body
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Omega-3 Stable COPD Lower TNF
Protein (BCAA) COPD Patients Enhanced who
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Improved daily
& energy meta
Improved cogn
Vitamin D COPD patients Reduced risk o
deficient patie
BCAAZ branched chain amino acid; COPDZ chronic obstructive pulm
Ref. Z reference; RQ Z respiratory quotient; TNF Z tumor necrosisenergy intake were observed with improvements in body
weight and handgrip strength.25 The results from these
meta-analyses clearly indicate that additional nutritional
supplementation together with nutritional advice, provides
significant increases in body weight, muscle strength, and
improved quality of life, which may lead to improved
mortality rates.Nutritional supplementation with high-fat and
high-carbohydrate formulations
Although it is desirable to increase the body weight of
malnourished COPD patients, challenges may exist as these
patients have a higher resting energy expenditure resulting
in a greater calorie requirement than in mild COPD pa-
tients. Furthermore, these patients may have increasing
fatigue, dyspnea, and early satiety, which affect their
ability to eat and consume enough calories. Therefore,
under these circumstances, it is important to provide
nutrition that has high calorie density. This will also help to
minimize abdominal distention that may cause discomfort
while eating.
It has been proposed that increasing the calorie intake
of COPD patients through a higher fat content diet may be
more beneficial, as fat produces less metabolic CO2 (VCO2)
per O2, and has a lower respiratory quotient (RQ) compared
with carbohydrate (CHO) metabolism. This may be partic-
ularly important in COPD patients with hypercapnia and
those suffering from shortness of breath. Several studies
have been performed to investigate the beneficial effects
of different types of nutritional supplements in COPD pa-
tients, and the results of these studies are summarized in
Table 1.clinical outcomes in COPD patients.
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to advanced pulmonary disease given low-, medium-, and
high-CHO diets by enteral feeding, demonstrated that CO2
production was significantly reduced in the high-fat
formulation (28% CHO, 55% fat) compared with two higher
CHO content formulations (53% CHO and 30% fat; 81.5% CHO
and 0.70% fat), and also with a lower RQ.26 The high-fat
formulation also appeared to be less likely to impair exer-
cise performance in these patients as determined by
workload, FEV1, and ventilation.
27
When moderate to severe COPD patients were given the
high-fat nutritional supplement (28% CHO, 55% fat, and 17%
protein), they had significantly improved arterial oxygen
levels, compared with those patients on a high-CHO diet
(60e70% CHO, 20e30% fat, and 15% protein).28 In a similar
comparison of nutritional supplementation in clinically
stable ambulatory COPD patients, high-fat diet was found
to be more beneficial than a high-CHO diet. There were
significantly higher levels of CO2 production, O2 consump-
tion, RQ, and minute ventilation up to 1.5 hours after
administration in those given the high-CHO diet, compared
with the high-fat diet.29 Comparison of a high-, medium-,
and low-CHO diet (the low CHO contained 28% CHO and 55%
fat) demonstrated that significantly lower CO2 production,
RQ, and arterial CO2 were observed in COPD patients on the
high-fat diet, and lung function improved with FEV1 values
increasing by 22%.30
People with COPD have difficulty inhaling enough O2 and
struggle to expire CO2 from their lungs, resulting in
elevated CO2 levels in the blood and respiratory acidosis.
Hypercapnia is a potentially fatal condition with symptoms
including shortness of breath, drowsiness, dizziness,
confusion, and headache. In patients who were on artificial
ventilation as a result of severe chronic obstructive airway
disease, those fed enterally with the high-fat formulation
had significantly reduced PaCO2 levels and reduced time on
the ventilator compared with patients in the standard
feeding group.31 These results suggest that a high-fat, low-
CHO formula given by enteral feeding, may be beneficial to
severe COPD patients on artificial ventilation. However,
there were some studies that appear to provide contra-
dictory evidence regarding the use of high-fat over high-
CHO formulas. A retrospective review of six small studies
with a total of 152 patients showed a lack of clinical benefit
with high-fat formulas, suggesting that they should not be
routinely used, but only be made available for severely
malnourished COPD patients on ventilatory support.32 When
patients with moderate to severe COPD were given either a
moderate-fat or high-fat enteral formula, individuals given
the high-fat meal experienced significantly delayed gastric
emptying.33 Following both moderate and high-fat meals,
CO2 production and O2 consumption both increased, with
significantly higher levels at 30 minutes and 90 minutes
after the moderate-fat meal (presumably because of
earlier gastric emptying). Patients receiving the high-fat
diet compared with a moderate-fat diet, had delayed
gastric emptying and increased feeling of satiety, further
exacerbating their malnourished state.34 It has been sug-
gested that hospitalized mechanically ventilated COPD
patients do not benefit to the same extent as ambulatory
patients when using high-fat formulas because of the
increased gastric clearance time.32 Further investigationsare needed to determine the benefits of high-fat over high-
CHO diets, especially when considering the different re-
quirements of COPD patients according to their disease
severities.
A diet high in carbohydrate compared to a diet high in
fat is thought to increase the relative metabolic production
of CO2 (VCO2) and the RQ and so increase the respiratory
demand in COPD patients. The nutrition a COPD patient
requires should be the appropriate amount of calories for
that patient without increasing VCO2. In mechanically
ventilated patients given enteral formulations containing
varying levels of carbohydrates or total calories (1, 1.5, or 2
times the basal energy expenditure), CO2 production
significantly increased with increases in total calories, but
was unaffected by the different CHO regimens.35 Avoidance
of overfeeding may be a significant factor, rather than the
amount of CHO intake, in avoiding hypercapnia.
In an attempt to prevent weight loss, sarcopenia, and
cachexia in COPD patients, a number of studies have been
performed to look at various nutritional supplements. When
COPD patients were given an oral supplement containing a
slightly higher calories (>10 kcal/kg/d) than standard
hospital feeding, there was some improvement in lung
function, but no significant effect on muscle strength or
wasting.28 COPD patients given nutritional supplementation
drinks containing 61% carbohydrate (CHO), 19% fat, and 20%
protein, up to three times a day for 8 weeks, had a signif-
icant increase in body weight, FFM, handgrip strength, and
respiratory function compared with a historical placebo
group.36 Similarly, in a study where COPD patients were
given a high-CHO oral nutritional supplement consisting of
83% CHO, given three times a day with pulmonary rehabil-
itation through exercise, significantly increased body
weight, body mass index, FFMI, and also mid-thigh cross-
sectional area were observed when both exercise and
nutritional supplement were combined.37 When COPD pa-
tients received dietary counseling and advice on nutritional
supplementing for 6 months, they consumed more energy
(194 kcal/d more than the control group), gained and
maintained weight, but with no differences in respiratory
and muscle function.38 These studies confirmed that COPD
patients benefitted from extra calories for a sustained
period combined with exercise. It would be interesting to
investigate what specific nutritional requirements can be
tailored for COPD patients.Nutritional supplementation with anti-
inflammatory omega-3
Anti-inflammatory supplements may improve the prognosis
for COPD patients. It has been shown that the balance
between omega-3 levels and omega-6 levels determines
whether these eicosanoids have anti- or proinflammatory
effects in patients with COPD.39 Omega-3 (n-3 PUFA) has an
anti-inflammatory effect through its ability to compete
with omega-6 (n-6 PUFA) to prevent production of proin-
flammatory eicosanoids.
In a study of 250 clinically stable COPD patients using
dietary data from a 122-item questionnaire, it was shown
that high levels of anti-inflammatory omega-3 fatty acid a-
linolenic acid in the patients’ diet was associated with low
Nutritional supplementation in COPD patients 599levels of the inflammatory cytokine, TNF.40 Conversely, a
diet high in a proinflammatory omega-6 fatty acid, arach-
idonic acid, indicated higher serum levels of the inflam-
matory cytokine, IL-6, and C-reactive protein.40 These
results suggest that COPD patients should be encouraged to
increase dietary omega-3 fatty acids (e.g., herring, sardine,
mackerel, salmon, halibut, tuna, sword fish, green-shelled
mussels) to promote the anti-inflammatory benefits of this
supplement, while avoiding foods dense in omega-6 fatty
acids (e.g., poultry, eggs, nuts, cereal, palm oil, and sun-
flower oil, catfish) so that their condition does not worsen
by elevating systemic IL-6 levels. There was no apparent
association between IL-8 and omega-3 intake, possibly
because it was difficult to measure serum IL-8 levels as it is
a more localized cytokine involved in recruitment and
activation of neutrophils in the lung (produced by acti-
vated, resident macrophages), rather than systemic,
circulating cytokines (such as TNF and IL-6).39,40 This was
supported by data that smokers with emphysema have
increased levels of IL-8 in bronchoalveolar lavage sam-
ples.40 These results suggest that omega-3 supplementation
may be beneficial in helping with an anti-inflammatory
response in COPD patients.Nutritional supplementationdessential amino
acids and BCAAs
Another area where supplementation may be useful is in
the use of essential amino acids (EAAs) or BCAAs essential
for building protein, as nutritional supplements. An imbal-
ance between muscle protein synthesis and breakdown
results in skeletal muscle cell wasting. Sarcopenia occurs as
part of the normal aging process (>50 years) as muscle
protein synthesis declines, along with a loss in muscle
quality and strength (where muscle fibers are replaced with
fat), with an increase in fibrosis, changes in muscle meta-
bolism, oxidative stress, and degeneration of the neuro-
muscular junction. This loss of FFM and change to fat is
accelerated in about 30% of patients with moderate to se-
vere COPD.41 This can exacerbate the problems that COPD
patients have with a lack of exercise, and increases the risk
of further deterioration in their respiratory and peripheral
muscle function.41 Skeletal muscle dysfunction may result
from an array of pathophysiological conditions in COPD such
as inflammation, malnutrition, and oxidative stress.19,41
In COPD patients with accelerated loss of FFM, there is a
direct correlation between low plasma concentrations of
BCAA and low FFM body composition and muscle energy
metabolism.19,42 The dietary supplementation of a soy
protein meal with BCAA enhanced whole-body protein
synthesis in patients with COPD.43
In a study of 32 severe COPD patients, oral supplemen-
tation with EAAs for 12 weeks increased FFM by 10% and had
beneficial effects on muscle energy metabolism, cognitive
function, and perception of health status.44 In a subsequent
study performed in 88 COPD outpatients, supplementation
with EAAs for 12 weeks significantly improved their quality
of life and their ability to perform their daily life routines,
as well as increasing FFM, muscle strength, and cognitive
function.45 It appears that in all these studies, supple-
menting with EAAs and BCAAs provides significantnutritional benefits to COPD patients in terms of muscle cell
growth and strength, especially in malnourished COPD
patients.Nutritional supplementationdvitamins and
minerals
Unsurprisingly, malnourished COPD patients have also been
shown to have decreased levels of vitamins, minerals, and
antioxidants as a result of poor nutrition, smoking, and
cachexia.34 Vitamin D deficiency may be common among
COPD patients as intake through food may be limited, and
their exposure to the sun is reduced because of a decline in
their outdoor activity. Skeletal muscles have vitamin D re-
ceptors, and it has been suggested that vitamin D defi-
ciency causes muscle weakness.46 Vitamin D deficiency can
precipitate or exacerbate osteopenia and osteoporosis,
cause osteomalacia and muscle weakness, and increase the
risk of fracture.46 Vitamin D is also thought to protect the
body against viral and bacterial infections that can trigger
COPD attacks.
It has been shown that performance speed and proximal
muscle strength were markedly improved when 25-
hydroxyvitamin D levels increased from 4 ng/mL to 16 ng/
mL, and this continued to improve as the concentration
increased above 40 ng/mL.46 In COPD patients with less
than 10 ng/mL of serum 25-hydroxyvitamin D, it was found
that patients had a reduced risk of COPD exacerbations
following vitamin D supplements.47 Low serum levels of 25-
hydroxyvitamin D were also shown to directly correlate
with poor FEV1 values.
46 By contrast, a longitudinal study of
356 moderate, severe, and very severe COPD patients were
assessed for an association between serum levels of vitamin
D and exacerbations, but no association was found.48
To study the effects of antioxidant and minerals, a
comprehensive examination of the independent associa-
tions of a wide range of serum markers of nutritional status
with lung function was conducted in 14,120 individuals.
Using data from a cross-sectional population nutrition sur-
vey, serum levels of antioxidant vitamins (vitamin A,
betacryptoxanthin, vitamin C, and vitamin E), selenium,
calcium, chloride, and iron were independently associated
with higher FEV1 values. Higher concentrations of potas-
sium and sodium were associated with lower FEV1.
49 A study
in older Chinese adults (>55 years) given daily doses of
antioxidant vitamins and increased dietary fish intake, and
supplementary omega-3 significantly improved lung func-
tion in these COPD patients.50 The results from these
studies suggest that additional supplementation with vita-
mins, minerals, and antioxidants would be beneficial to the
outcome of COPD patients.Discussion
The goal of effective COPD management is to relieve
symptoms, slow disease progression, improve exercise
tolerance, prevent and treat complications, and improve
nutritional status and overall quality of life. There is a
mounting body of evidence to indicate that nutritional
supplementation to increase body weight, FFM, and fat
600 M.-J. Hsieh et al.mass, and to lower RQ and CO2 levels in the blood provides
significant benefits for the prognosis of COPD patients.
To achieve this, a high-fat supplement may be beneficial
in providing low volume, calorie dense nutrition especially
to malnourished COPD patients with satiety problems, as it
has been shown to produce less CO2 and result in a lower RQ
value compared with high-CHO diets. In addition,
increasing the amount of omega-3 in the diet or through
supplementation may help provide important anti-
inflammatory benefits to COPD patients. More specific
supplements containing EAAs and BCAAs in combination
with exercise may be helpful for increasing muscle strength
and increasing FFM, together with vitamin D and other
mineral supplements, which may improve the quality of life
in COPD patients. Further studies to look at combining
these nutritional supplements could be extremely useful
and would provide a relatively cheap and simple method to
improve clinical outcomes of COPD patients.References
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